Imeik Technology Development Co

Imeik Technology Development Co Total Assets

The Total Assets of Imeik Technology Development Co (300896.SZ) as of Oct 20, 2026 is 8.91 B CNY. In the previous year, Total Assets was 8.34 B CNY — a change of 6.80% (higher).

Total Assets

8.91 BCNY

YoY

6.80%

Last updated:

Total Assets of Imeik Technology Development Co is 2025 8.91 B CNY. Total Assets of Imeik Technology Development Co was 2024 8.34 B CNY. It decreases by 6.80% higher compared to the previous year.

The Imeik Technology Development Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
463.61 M CNY
Jan 1, 2019
743.65 M CNY
Jan 1, 2020
4.67 B CNY
Jan 1, 2021
5.27 B CNY
Jan 1, 2022
6.26 B CNY
Jan 1, 2023
6.85 B CNY
Jan 1, 2024
8.34 B CNY
Jan 1, 2025
8.91 B CNY
The Imeik Technology Development Co Total Assets history
YEARTotal AssetsYoY
8.91 BCNY+6.80%
8.34 BCNY+21.72%
6.85 BCNY+9.49%
6.26 BCNY+18.71%
5.27 BCNY+12.85%
4.67 BCNY+528.21%
743.65 MCNY+60.40%
463.61 MCNY+16.95%
396.41 MCNY+26.30%
313.86 MCNY+81.79%
172.64 MCNY+63.97%
105.29 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Total Assets of Imeik Technology Development Co is 8.91 B CNY in 2025.

Total Assets of Imeik Technology Development Co changed from 8.34 B CNY to 8.91 B CNY, representing a 6.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Imeik Technology Development Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co